-
Mashup Score: 2
Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial. #gyncsm #oncology #SGO22 https://t.co/s4QsS29GLw https://t.co/S1tB1krUvf
-
-
Mashup Score: 0Ociperlimab/Tislelizumab Combo Under Exploration in Previously Treated Recurrent or Metastatic Cervical Cancer - 2 year(s) ago
The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer. #gyncsm #SGO22 #oncology https://t.co/uBZQE6nShm
-
-
Mashup Score: 0Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic - 2 year(s) ago
Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic @peterketch92 @uabmedicine @SGO_org #gyncsm #COVID19 #SGO22 https://t.co/nRc2nLilxh
-
-
Mashup Score: 0Prolonging Survival in Patients With Advanced Ovarian Cancer - 2 year(s) ago
A subanalysis of the GOG 252 trial revealed factors associated with longer survival among patients with stage II-III epithelial ovarian cancer.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers observed a median overall survival of approximately 9 years, regardless of the chemotherapy regimen patients received. Presented at @SGO_org #SGO22 with @UofOklahoma. https://t.co/bRkDIbO994 #OvarianCancer #SGOmtg
-
-
Mashup Score: 0Molecularly Targeted Therapy May Improve Survival in Advanced, Recurrent Endometrial Cancer - 2 year(s) ago
In a real-world study, more than 54% of patients had at least 1 potentially actionable genomic alteration.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Real-world data suggests that #molecularlytherapy may improve survival in patients with advanced or recurrent #endometrialcancer. Presented at @SGO_org #SGO22 with @DukeHealth @dukeobgyn. https://t.co/9DZhOgLI4R #SGOmtg
-
-
Mashup Score: 0
Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Jyoti Mayadev, MD, of @UCSDHealth, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in locally advanced, node-positive cervical cancer. #gyncsm #SGO22 https://t.co/K6OLzsLrod https://t.co/L3pTN8iFLO
-
-
Mashup Score: 1Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer - 2 year(s) ago
Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial. @MountSinaiMiami @SGO_org #SGO22 #gyncsm https://t.co/QNvKT1PXsc https://t.co/EVZdJDyHVV
-
-
Mashup Score: 0Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma - 2 year(s) ago
Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma. @NorthwellHealth #gyncsm #SGO22 https://t.co/tVk9Aywcne https://t.co/KevIwitu6I
-
-
Mashup Score: 0Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma - 2 year(s) ago
Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study. @nyulangone @Perlmutter_CC #SGO22 #gyncm https://t.co/gpYAyBVZtm https://t.co/MnLz67Y3TJ
-
Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial. #gyncsm #oncology #SGO22 https://t.co/OBzr73msSk